|
"yen c j"的相關文件
顯示項目 46-70 / 471 (共19頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
| 國立成功大學 |
2022 |
Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study: RAM/PL + BSC for advanced HCC
|
Shao, G.;Bai, Y.;Yuan, X.;Chen, X.;Gu, S.;Gu, K.;Hu, C.;Liang, H.;Guo, Y.;Wang, J.;Yen, C.-J.;Lee, V.H.-F.;Wang, C.;Widau, R.C.;Zhang, W.;Liu, J.;Zhang, Q.;Qin, S. |
| 國立成功大學 |
2022 |
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin
|
Chiu, T.-J.;Yang, S.-H.;Chiu, S.-C.;Hsueh, S.-W.;Chiang, N.-J.;Li, C.-P.;Bai, L.-Y.;Cheng, F.-M.;Chuang, S.-C.;Shan, Y.-S.;Chan, D.-C.;Chen, L.-T.;Yen, C.-J.;Peng, C.-M.;Su, Y.-Y.;Chen, Y.-Y.;Chen, J.-S.;Chou, W.-C. |
| 國立成功大學 |
2022 |
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
|
Simonelli, M.;Garralda, E.;Eskens, F.;Gil-Martin, Martin M.;Yen, C.-J.;Obermannova, R.;Chao, Y.;Lonardi, S.;Melichar, B.;Moreno, V.;Yu, M.-L.;Bongiovanni, A.;Calvo, E.;Rottey, S.;Machiels, J.-P.;Gonzalez-Martin, A.;Paz-Ares, L.;Chang, Chang C.-L.;Mason, W.;Lin, C.-C.;Reardon, D.A.;Vieito, M.;Santoro, A.;Meng, R.;Abbadessa, G.;Menas, F.;Lee, H.;Liu, Q.;Combeau, Combeau C.;Ternes, N.;Ziti-Ljajic, S.;Massard, C. |
| 國立成功大學 |
2022 |
Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety
|
Shao, Y.-Y.;Feng, Y.-H.;Yen, C.-J.;Yang, T.-S.;Shen, Y.-C.;Chao, Y.;Chen, J.-S.;Su, C.-Y.;Chen, W.-J.;Hsiang, Hsiang H.-L.;Hsu, C.-H. |
| 國立成功大學 |
2022 |
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
|
Chan, S.L.;Schuler, M.;Kang, Y.-K.;Yen, C.-J.;Edeline, J.;Choo, S.P.;Lin, C.-C.;Okusaka, T.;Weiss, K.-H.;Macarulla, T.;Cattan, S.;Blanc, J.-F.;Lee, K.-H.;Maur, Maur M.;Pant, S.;Kudo, M.;Assenat, E.;Zhu, A.X.;Yau, T.;Lim, H.Y.;Bruix, J.;Geier, A.;Guill�n-Ponce, C.;Fasolo, A.;Finn, R.S.;Fan, J.;Vogel, A.;Qin, S.;Riester, M.;Katsanou, V.;Chaudhari, M.;Kakizume, T.;Gu, Y.;Porta, D.G.;Myers, A.;Delord, J.-P. |
| 國立成功大學 |
2022 |
Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
|
Zhu, A.X.;Dayyani, F.;Yen, C.-J.;Ren, Z.;Bai, Y.;Meng, Z.;Pan, H.;Dillon, P.;Mhatre, S.K.;Gaillard, V.E.;Hernandez, S.;Kelley, R.K.;Sangro, B. |
| 國立成功大學 |
2022 |
NEIL3 promotes hepatoma epithelial–mesenchymal transition by activating the BRAF/MEK/ERK/TWIST signaling pathway
|
Lai, H.-H.;Hung, L.-Y.;Yen, C.-J.;Hung, Hung H.-C.;Chen, R.-Y.;Ku, Y.-C.;Lo, H.-T.;Tsai, H.-W.;Lee, Y.-P.;Yang, T.-H.;Chen, Y.-Y.;Huang, Y.-S.;Huang, W. |
| 臺大學術典藏 |
2021-11-17T07:23:43Z |
Functional assessment of chronic illness therapy-the fatigue scale exhibits stronger associations with clinical parameters in chronic dialysis patients compared to other fatigue-assessing instruments
|
Chao C.-T.; Huang J.-W.; Chiang C.-K.; Yen C.-J.; Hung Y.-C.; Hsu S.-H.; CHI-YUAN SHIH; Lai C.-F.; Chan D.-C.D.; Hung K.-Y.; Chu T.-S.; Huang S.-J.; COGENT (COhort of GEriatric Nephrology in NTUH) study group |
| 臺大學術典藏 |
2021-08-31T06:42:27Z |
Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer
|
Shen Y.-C.; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; Lin Z.-Z.; Chen L.-T.; Su W.-C.; Chao Y.; Yeh K.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:42:22Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.; Su W.-C.; Yen C.-J.; Hsu C.-H.; Su W.-P.; Yeh K.-H.; Lu Y.-S.; ANN-LII CHENG; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:38Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; Lin Z.-Z.; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; ANN-LII CHENG; Carrasquilo J.A. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib
|
Meyer T.; Palmer D.H.; ANN-LII CHENG; Hocke J.; Loemb? A.-B.; Yen C.-J. |
| 臺大學術典藏 |
2021-08-31T06:29:28Z |
A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
|
Yen C.-J.; Kim T.-Y.; Feng Y.-H.; Chao Y.; Lin D.-Y.; Ryoo B.-Y.; Huang D.C.-L.; Schnell D.; Hocke J.; Loemb? A.-B.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:21Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.; Martinelli E.; ANN-LII CHENG; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Shen Y.-C.; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:13Z |
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression
|
Ryoo B.-Y.; ANN-LII CHENG; Ren Z.; Kim T.-Y.; Pan H.; Rau K.-M.; Choi H.J.; Park J.-W.; Kim J.H.; Yen C.J.; Lim H.Y.; Zhou D.; Straub J.; Scheele J.; Berghoff K.; Qin S. |
| 臺大學術典藏 |
2021-08-24T05:21:51Z |
Lean Body Mass Predicts Long-Term Survival in Chinese Patients on Peritoneal Dialysis
|
Huang J.-W.; Lien Y.-C.; Wu H.-Y.; Yen C.-J.; Pan C.-C.; Hung T.-W.; CHI-TING SU; Chiang C.-K.; Cheng H.-T.; Hung K.-Y. |
| 臺大學術典藏 |
2021-08-20T08:19:53Z |
Citrobacter peritoneal dialysis peritonitis: Rare occurrence with poor outcomes
|
CHIA-TER CHAO; Lee S.-Y.; Yang W.-S.; Chen H.-W.; Fang C.-C.; Yen C.-J.; Chiang C.-K.; Hung K.-Y.; Huang J.-W. |
| 臺大學術典藏 |
2021-08-20T08:19:53Z |
Peritoneal dialysis peritonitis by anaerobic pathogens: A retrospective case series
|
CHIA-TER CHAO; Lee S.-Y.; Yang W.-S.; Chen H.-W.; Fang C.-C.; Yen C.-J.; Chiang C.-K.; Hung K.-Y.; Huang J.-W. |
| 臺大學術典藏 |
2021-08-20T08:19:52Z |
A rare and under-recognized pathogen in peritoneal dialysis peritonitis: Corynebacterium jeikeium
|
CHIA-TER CHAO; Huang J.W.; Yen C.J. |
| 臺大學術典藏 |
2021-08-20T08:19:50Z |
Serum vitamin D levels are positively associated with varicella zoster immunity in chronic dialysis patients
|
CHIA-TER CHAO; Lee S.-Y.; Yang W.-S.; Yen C.-J.; Chiang C.-K.; Huang J.-W.; Hung K.-Y. |
| 臺大學術典藏 |
2021-08-20T08:19:49Z |
Acinetobacter peritoneal dialysis peritonitis: A changing landscape over time
|
CHIA-TER CHAO; Lee S.-Y.; Yang W.-S.; Chen H.-W.; Fang C.-C.; Yen C.-J.; Chiang C.-K.; Hung K.-Y.; Huang J.-W. |
| 臺大學術典藏 |
2021-08-20T08:19:48Z |
Sequence variants of peroxisome proliferator-activated receptor-gamma gene and the clinical courses of patients with end-stage renal disease
|
CHIA-TER CHAO; Chen Y.-C.; Chiang C.-K.; Huang J.-W.; Hu F.-C.; Fang C.-C.; Chang C.-C.; Yen C.-J. |
| 臺大學術典藏 |
2021-08-20T08:19:47Z |
Intradialytic hypotension and cardiac remodeling: A vicious cycle
|
CHIA-TER CHAO; Huang J.-W.; Yen C.-J. |
顯示項目 46-70 / 471 (共19頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
|
